CoChat

Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy

Michel, Lars, Helfrich, Iris, Hendgen-Cotta, Ulrike Barbara, Mincu, Raluca-Ileana, Korste, Sebastian, Mrotzek, Simone Maria, Spomer, Armin, Odersky, Andrea, Rischpler, Christoph, Herrmann, Ken, Umutlu, Lale, Coman, Cristina, Ahrends, Robert, Sickmann, Albert, Löffek, Stefanie, Livingstone, Elisabeth, Ugurel, Selma, Zimmer, Lisa, Gunzer, Matthias, Schadendorf, Dirk, Totzeck, Matthias, Rassaf, Tienush · 2022 · European Heart Journal
Cited by 168

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Aims: Cardiac immune-related adverse events (irAEs) from immune checkpoint inhibition (ICI) targeting programmed death 1 (PD1) are of growing concern. Once cardiac irAEs become clinically manifest, fatality rates are high. Cardio-oncology aims to prevent detrimental effects before manifestation of severe complications by targeting early pathological changes. We therefore aimed to investigate early consequences of PD1 inhibition for cardiac integrity to prevent the development of overt cardiac disease. Methods and results: We investigated cardiac-specific consequences from anti-PD1 therapy in a combined biochemical and in vivo phenotyping approach. Mouse hearts showed broad expression of the ligand PDL1 on cardiac endothelial cells as a main mediator of immune-crosstalk. Using a novel melanoma mouse model, we assessed that anti-PD1 therapy promoted myocardial infiltration with CD4+ and CD8+ T cells, the latter being markedly activated. Left ventricular (LV) function was impaired during pharmacological stress, as shown by pressure–volume catheterization. This was associated with a dysregulated myocardial metabolism, including the proteome and the lipidome. Analogous to the experimental approach, in patients with metastatic melanoma (n = 7) receiving anti-PD1 therapy, LV function in response to stress was impaired under therapy. Finally, we identified that blockade of tumour necrosis factor alpha (TNFα) preserved LV function without attenuating the anti-cancer efficacy of anti-PD1 therapy. Conclusions: Anti-PD1 therapy induces a disruption of cardiac immune homeostasis leading to early impairment of myocardial functional integrity, with potential prognostic effects on the growing number of treated patients. Blockade of TNFα may serve as an approach to prevent the manifestation of ICI-related cardiotoxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehab430

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 168

Metadata

Authors
Michel, L., Helfrich, I., Hendgen-Cotta, U. B., Mincu, R.-I., Korste, S., Mrotzek, S. M., Spomer, A., Odersky, A., Rischpler, C., Herrmann, K., Umutlu, L., Coman, C., Ahrends, R., Sickmann, A., Löffek, S., Livingstone, E., Ugurel, S., Zimmer, L., Gunzer, M., Schadendorf, D., Totzeck, M., & Rassaf, T.
Venue
European Heart Journal
Published
2021-08-14
Volume
43
Issue
4
Pages
316-329
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W3188167194
Cited by
168
References
12
FWCI
8.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. https://app.cochat.ai/papers/10.1093/eurheartj/ehab430
The paper
Michel, L., Helfrich, I., Hendgen-Cotta, U. B., Mincu, R.-I., Korste, S., Mrotzek, S. M., Spomer, A., Odersky, A., Rischpler, C., Herrmann, K., Umutlu, L., Coman, C., Ahrends, R., Sickmann, A., Löffek, S., Livingstone, E., Ugurel, S., Zimmer, L., Gunzer, M., . . . Rassaf, T. (2022). Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. European Heart Journal. https://doi.org/10.1093/eurheartj/ehab430

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.